Clinical Trial

Phase I/II Study of SCTB41 Plus SCTB39-1with or Without Standard Therapy in Advanced Solid Tumours

Not Yet Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB41 in combination with SCTB39-1with or without standard therapy in adult patients with advanced malignant solid tumours. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial.
Trial Details
NCT Number NCT07594028
Lead Sponsor Sinocelltech Ltd.
Conditions Advanced Malignant Solid Tumor
Enrollment 126 participants
Start Date 2026-05-30
Primary Completion 2029-05-30 (estimated)
Study Completion 2029-05-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-18